دورية أكاديمية
Outcomes of Conversion Surgery for Patients With Low-Risk Papillary Thyroid Carcinoma.
| العنوان: | Outcomes of Conversion Surgery for Patients With Low-Risk Papillary Thyroid Carcinoma. |
|---|---|
| المؤلفون: | Levyn H; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York., Scholfield DW; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York., Eagan A; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York., Boe LA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York., Shaha AR; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York., Wong RJ; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York., Shah JP; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York., Ganly I; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York., Morris LGT; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York., Tuttle RM; Endocrinology Service, Memorial Sloan Kettering Cancer Center, New York, New York. |
| المصدر: | JAMA otolaryngology-- head & neck surgery [JAMA Otolaryngol Head Neck Surg] 2024 May 15. Date of Electronic Publication: 2024 May 15. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101589542 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2168-619X (Electronic) Linking ISSN: 21686181 NLM ISO Abbreviation: JAMA Otolaryngol Head Neck Surg Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Chicago, IL : American Medical Association, [2013]- |
| مستخلص: | Importance: The outcomes of patients with low-risk thyroid cancer who undergo surgery following a period of active surveillance (AS) are not well-defined. Objective: To evaluate surgical, pathologic, and oncologic outcomes among patients undergoing conversion surgery (CS) following AS for low-risk papillary thyroid carcinoma. Design, Setting, and Participants: In this cohort study, patients who underwent CS for disease progression were compared with patients who underwent CS without disease progression and with a propensity score-matched cohort of patients who underwent initial surgery (IS). The median (IQR) postsurgical follow-up time was 40.3 (18.0-59.0) months. Patients were treated at a quaternary cancer referral center in the United States. Exposures: Surgery. Main Outcomes and Measures: Surgical complications, pathologic characteristics, overall survival (OS), and recurrence-free survival (RFS). Results: Of 550 patients who underwent AS, 55 (10.0%) had CS, of whom 39 (7.1%) had surgery due to suspected disease progression (median [IQR] age, 48 [39-56] years; 32 [82.1%] female). There were no clinically meaningful differences in rates of surgical sequalae between the progression CS group (12 of 39 [30.7%]) and the nonprogression CS group (7 of 16 [43.8%]) (Cramer V, 0.2; 95% CI, 0.01-0.5). The 5-year OS was 100% (95% CI, 100%-100%) in both the disease-progression CS cohort and the IS cohort. Although the cohort of patients undergoing CS after disease progression was by definition a subset with more aggressive tumor behavior, no clinically meaningful differences were observed in the rates of regional recurrence (2 of 39 [5.1%] vs 0 of 39 patients with IS), local recurrence (0 patients), distant metastasis (0 patients), or disease-specific mortality (0 patients) when compared with the matched IS group. Five-year RFS rates were similar: 100% in the IS group and 86% (95% CI, 70%-100%) in the CS group. Conclusions and Relevance: In this cohort study, CS for suspected disease progression was associated with surgical and oncologic outcomes similar to IS, supporting the feasibility and safety of AS for patients with low-risk papillary thyroid carcinoma. |
| References: | Thyroid. 2022 Nov;32(11):1337-1345. (PMID: 36178355) Thyroid. 2022 Nov;32(11):1328-1336. (PMID: 36205563) Thyroid. 2019 Oct;29(10):1399-1408. (PMID: 31368412) Eur J Surg Oncol. 2023 Sep;49(9):106917. (PMID: 37137793) Thyroid. 2023 Jul;33(7):817-825. (PMID: 37166389) World J Surg. 2010 Jan;34(1):28-35. (PMID: 20020290) Thyroid. 2003 Apr;13(4):381-7. (PMID: 12804106) Lancet. 2013 Mar 23;381(9871):1046-57. (PMID: 23668555) Thyroid. 2012 Nov;22(11):1144-52. (PMID: 23083442) N Engl J Med. 2016 Aug 18;375(7):614-7. (PMID: 27532827) Thyroid. 2022 Jan;32(1):28-36. (PMID: 34861772) Endocr J. 2023 Apr 28;70(4):411-418. (PMID: 36631086) Thyroid. 2018 Dec;28(12):1587-1594. (PMID: 30226447) Thyroid. 2016 Jan;26(1):1-133. (PMID: 26462967) Lancet. 2016 Dec 3;388(10061):2783-2795. (PMID: 27240885) |
| تواريخ الأحداث: | Date Created: 20240515 Latest Revision: 20240518 |
| رمز التحديث: | 20240518 |
| مُعرف محوري في PubMed: | PMC11097095 |
| DOI: | 10.1001/jamaoto.2024.1699 |
| PMID: | 38749064 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2168-619X |
|---|---|
| DOI: | 10.1001/jamaoto.2024.1699 |